Cargando…
Pneumatocele during sorafenib therapy: first report of an unusual complication
Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/ https://www.ncbi.nlm.nih.gov/pubmed/29464101 http://dx.doi.org/10.18632/oncotarget.23599 |
_version_ | 1783300310338371584 |
---|---|
author | Sangro, Paloma Bilbao, Idoia Fernández-Ros, Nerea Iñarrairaegui, Mercedes Zulueta, Javier Bilbao, JI Sangro, Bruno |
author_facet | Sangro, Paloma Bilbao, Idoia Fernández-Ros, Nerea Iñarrairaegui, Mercedes Zulueta, Javier Bilbao, JI Sangro, Bruno |
author_sort | Sangro, Paloma |
collection | PubMed |
description | Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement. |
format | Online Article Text |
id | pubmed-5814241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58142412018-02-20 Pneumatocele during sorafenib therapy: first report of an unusual complication Sangro, Paloma Bilbao, Idoia Fernández-Ros, Nerea Iñarrairaegui, Mercedes Zulueta, Javier Bilbao, JI Sangro, Bruno Oncotarget Case Report Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement. Impact Journals LLC 2017-12-22 /pmc/articles/PMC5814241/ /pubmed/29464101 http://dx.doi.org/10.18632/oncotarget.23599 Text en Copyright: © 2018 Sangro et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Case Report Sangro, Paloma Bilbao, Idoia Fernández-Ros, Nerea Iñarrairaegui, Mercedes Zulueta, Javier Bilbao, JI Sangro, Bruno Pneumatocele during sorafenib therapy: first report of an unusual complication |
title | Pneumatocele during sorafenib therapy: first report of an unusual complication |
title_full | Pneumatocele during sorafenib therapy: first report of an unusual complication |
title_fullStr | Pneumatocele during sorafenib therapy: first report of an unusual complication |
title_full_unstemmed | Pneumatocele during sorafenib therapy: first report of an unusual complication |
title_short | Pneumatocele during sorafenib therapy: first report of an unusual complication |
title_sort | pneumatocele during sorafenib therapy: first report of an unusual complication |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814241/ https://www.ncbi.nlm.nih.gov/pubmed/29464101 http://dx.doi.org/10.18632/oncotarget.23599 |
work_keys_str_mv | AT sangropaloma pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT bilbaoidoia pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT fernandezrosnerea pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT inarrairaeguimercedes pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT zuluetajavier pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT bilbaoji pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication AT sangrobruno pneumatoceleduringsorafenibtherapyfirstreportofanunusualcomplication |